KR20060093554A - 다약제내성 억제 효과를 갖는 퀴놀린 유도체 및 이의 약제학적 조성물 - Google Patents
다약제내성 억제 효과를 갖는 퀴놀린 유도체 및 이의 약제학적 조성물 Download PDFInfo
- Publication number
- KR20060093554A KR20060093554A KR1020050014626A KR20050014626A KR20060093554A KR 20060093554 A KR20060093554 A KR 20060093554A KR 1020050014626 A KR1020050014626 A KR 1020050014626A KR 20050014626 A KR20050014626 A KR 20050014626A KR 20060093554 A KR20060093554 A KR 20060093554A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- drug resistance
- present
- quinoline
- quinoline derivatives
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050014626A KR100639163B1 (ko) | 2005-02-22 | 2005-02-22 | 다약제내성 억제 효과를 갖는 퀴놀린 유도체 및 이의 약제학적 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050014626A KR100639163B1 (ko) | 2005-02-22 | 2005-02-22 | 다약제내성 억제 효과를 갖는 퀴놀린 유도체 및 이의 약제학적 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060093554A true KR20060093554A (ko) | 2006-08-25 |
KR100639163B1 KR100639163B1 (ko) | 2006-10-30 |
Family
ID=37601652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050014626A KR100639163B1 (ko) | 2005-02-22 | 2005-02-22 | 다약제내성 억제 효과를 갖는 퀴놀린 유도체 및 이의 약제학적 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100639163B1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100880163B1 (ko) * | 2007-05-30 | 2009-02-04 | (주)바이오버드 | 신규한 다약제 내성 억제 화합물 및 이를 포함하는약제학적 조성물 |
KR20210092123A (ko) | 2020-01-15 | 2021-07-23 | 재단법인대구경북과학기술원 | 세포외 기질 및 항암제로 이루어진 접합체 및 이의 의학적 용도 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100429356B1 (ko) | 2001-04-23 | 2004-05-31 | 조수동 | 다약제 내성 극복 이소퀴놀린계 화합물 및 그 제조방법 |
KR100516075B1 (ko) | 2002-11-08 | 2005-09-22 | 한미약품 주식회사 | 신규한 p-당단백질 저해제 |
-
2005
- 2005-02-22 KR KR1020050014626A patent/KR100639163B1/ko active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100880163B1 (ko) * | 2007-05-30 | 2009-02-04 | (주)바이오버드 | 신규한 다약제 내성 억제 화합물 및 이를 포함하는약제학적 조성물 |
KR20210092123A (ko) | 2020-01-15 | 2021-07-23 | 재단법인대구경북과학기술원 | 세포외 기질 및 항암제로 이루어진 접합체 및 이의 의학적 용도 |
Also Published As
Publication number | Publication date |
---|---|
KR100639163B1 (ko) | 2006-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2803665B1 (en) | Synthesis of polyhydroxy benzopyran ketone compound and anti-tumor effect thereof | |
JP6920295B2 (ja) | テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用 | |
JP2010539104A (ja) | ヒストンデアセチラーゼhdac1、hdac2および/またはhdac3の選択的阻害剤ならびに微小管安定剤による癌の組合せ治療 | |
CN110418796A (zh) | 托法替尼(tofacitinib)的葡萄糖苷酸前药 | |
KR20180100663A (ko) | 대사 기능장애에 의하여 유도된 종양에 대한 치료 | |
US20200397798A1 (en) | Combination therapies with farnesoid x receptor (fxr) modulators | |
TW201119651A (en) | Pharmaceutical composition comprising indole compound | |
JP5934839B2 (ja) | ベルベノン誘導体を含有する退行性脳疾患治療または予防用薬学組成物 | |
KR20170131644A (ko) | 인단 아세트산 유도체를 사용한 간 질환의 치료 방법 | |
EP2380570A1 (en) | Pharmaceutical composition for preventing and treating diabetic nephropathy and preparation method thereof | |
KR100639163B1 (ko) | 다약제내성 억제 효과를 갖는 퀴놀린 유도체 및 이의 약제학적 조성물 | |
Zhang et al. | Synthesis and evaluation of andrographolide derivatives as potent anti-osteoporosis agents in vitro and in vivo | |
US11098052B2 (en) | 4-azapodophylotoxins compounds | |
US20100279964A1 (en) | Angular Pyranocoumarins, Process for Preparation and Uses Thereof | |
JP3507511B2 (ja) | アルグラビン(arglabin)およびアルグラビン誘導体の薬学的組成物 | |
KR101349752B1 (ko) | 정족수 감지 억제 활성 및 항균 활성을 갖는 항균용 조성물 | |
US20100105769A1 (en) | pharmaceutical composition containing daurinol for the prevention and treatment of cancers | |
JP2013512234A (ja) | 小型ピリミジン誘導体およびその使用の方法 | |
JP2013503908A (ja) | ニューロキニン2受容体活性に関連する障害または疾患を治療するための化合物 | |
CN111821303A (zh) | 沃替西汀及其盐在制备抗肿瘤药物中的应用 | |
CN111978330A (zh) | 黄烷醇-脂肪醇杂合体及其药物组合物与其制备方法和应用 | |
WO2015102380A1 (ko) | 신규한 8-옥소프로토베르베린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 nfat5의 활성 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2015101265A1 (zh) | 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途 | |
TW200812602A (en) | Anti-angiogenic composition | |
KR101423134B1 (ko) | 신규한 판카스타틴 화합물 및 그를 유효성분으로 포함하는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121022 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131018 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141020 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20151020 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170927 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20181022 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20191021 Year of fee payment: 14 |